Fingolimod versus interferon beta 1-a: Benefit–harm assessment approach based on TRANSFORMS individual patient data

BACKGROUND: Fingolimod is a disease-modifying drug approved for multiple sclerosis but its benefit–harm balance has never been assessed compared to other active treatments. OBJECTIVES: Our aim was to compare the benefits and harms of fingolimod with interferon beta-1a using individual patient data f...

Descripción completa

Detalles Bibliográficos
Autores principales: Spanu, Alessandra, Aschmann, Hélène E, Kesselring, Jürg, Puhan, Milo A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459487/
https://www.ncbi.nlm.nih.gov/pubmed/36092642
http://dx.doi.org/10.1177/20552173221117784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459487/
https://www.ncbi.nlm.nih.gov/pubmed/36092642
http://dx.doi.org/10.1177/20552173221117784

Ejemplares similares